Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vopratelimab - Concentra Biosciences

Drug Profile

Vopratelimab - Concentra Biosciences

Alternative Names: ICOS agonist monoclonal antibody; JTX-2011

Latest Information Update: 15 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jounce Therapeutics
  • Developer Concentra Biosciences
  • Class Antineoplastics; Cell therapies; Immunotherapies; Monoclonal antibodies; T lymphocyte cell therapies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Inducible T-cell co-stimulator protein agonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer; Solid tumours; Urogenital cancer

Most Recent Events

  • 01 May 2023 Jounce Therapeutics has been acquired and merged into Concentra Biosciences
  • 31 Jan 2023 Jounce Therapeutics completes a phase I/II trial in Solid tumours (Monotherapy, Combination therapy, Second-line therapy, Metastatic disease, Late-stage disease) in USA (IV) (NCT04319224)
  • 20 Sep 2022 Jounce Therapeutics completes the phase II EMERGE trial in Non-small cell lung cancer and Urogenital cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease, Second-line therapy or greater) in USA and Canada (IV) (NCT03989362)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top